medigraphic.com
Instituto Nacional de Salud Pública

2018, Number 1

<< Back Next >>

salud publica mex 2018; 60 (1)

Streptococcus pneumoniae: distribution of serotypes and antimicrobial susceptibility in patients with cancer

Soto-Noguerón A, Carnalla-Barajas MN, Cornejo-Juárez P, Volkow-Fernández P, Velázquez-Meza ME, Echániz-Aviles G

Language: English
References: 16
Page: 21-28
PDF size: 275.00 Kb.


ABSTRACT

Objective. To describe the distribution of pneumococcal serotypes causing infectious diseases in patients with hematological malignancies and solid tumors and their antimicrobial susceptibility before and after introduction of pneumococcal conjugate vaccine (PCV7) in Mexico. Materials and methods. Consecutive pneumococcal isolates from hospitalized patients from the SIREVA-network were serotyped using the Quellung reaction and antimicrobial susceptibility was performed using the broth microdilution method. Results. A total of 175 pneumococcal isolates were recovered, 105 from patients with hematological malignancies and 70 with solid tumors. Serotypes 19A (22.7%), 19F (20.4%), and 35B (17.7%) were the most frequent isolates in the first group and serotypes 3 (27.2%) and 19A (28.6%) in the second group. No decreased susceptibility to beta-lactams or TMP/SMX was observed after introduction of PCV7. Conclusions. An increase in non-vaccine types is observed without significate changes in antimicrobial susceptibility after introduction of PCV7.


REFERENCES

  1. Holland T, Fowler VG Jr., Shelburne SA 3rd. Invasive gram-positive bacterial infection in cancer patients. Clin Infect Dis. 2014; 59(suppl 5):S331-4. https://doi.org/10.1093/cid/ciu598

  2. Secretaría de Salud. Programa Sectorial de Salud 2013-2018. Cáncer en la Infancia y la Adolescencia. Mexico City: Secretaría de Salud, 2014.

  3. Consejo Nacional de Vacunación. Manual de Vacunación 2008-2009. Mexico City: SSa, 2008.

  4. Di Fabio JL, Homma A de QC. Pan American Health Organization epidemiological surveillance network for Streptococcus pneumoniae. Microb Drug Resist. 1997;3(2):131-3. https://doi.org/10.1089/mdr.1997.3.131

  5. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement. CLSI document M100-S23. 2014. Wayne, PA: Clinical and Laboratory Standards Institute, 2013.

  6. García-Vidal C, Ardanuy C, Gudiol C, Cuervo G, Calatayud L, Bodro M, et al. Clinical and microbiological epidemiology of Streptococcus pneumoniae bacteremia in cancer patients. J Infect. 2012;65(6):521-7. https:// doi.org/10.1016/j.jinf.2012.08.015

  7. Gudiol C, Royo-Cebrecos C, Laporte J, Ardanuy C, García-Vidal C, Antonio M, et al. Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients. Respirology. 2016;21(8):1411-

  8. https://doi.org/10.1111/resp.12848 8. Marin M, Gudiol C, Ardanuy C, García-Vidal C, Calvo M, Arnan M, et al. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours. J Infect. 2014;69(5):417-23. https://doi.org/10.1016/j.jinf.2014.05.018

  9. Shelburne SA 3rd, Tarrand J, Rolston KV. Review of streptococcal bloodstream infections at a comprehensive cancer care center, 2000-2011. J Infect. 2013;66(2):136-46. https://doi.org/10.1016/j.jinf.2012.11.007

  10. Phillips RS, Lehrnbecher T, Alexander S, Sung L. Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS One. 2012;7(5):e38300. https://doi.org/10.1371/journal.pone.0038300

  11. Echániz-Avilés G, San Román-Álvarez L, Sánchez-Alemán M, Carnalla- Barajas MN, Soto-Noguerón A. Prevalence of Streptococcus pneumoniae serotype 19A before and after the introduction of the heptavalent conjugate vaccine in Mexico. Salud Publica Mex. 2014;56(3):266-71. https://doi. org/10.21149/spm.v56i3.7344

  12. Cardoso NT, Santos BA, Barbosa AV, Superti SV, Teixeira LM, Neves FP. Serotypes, antimicrobial resistance and genotypes of Streptococcus pneumoniae associated with infections in cancer patients in Brazil. Diagn Microbiol Infect Dis. 2017;87(3):281-5. https://doi.org/10.1016/j.diagmicrobio. 2016.11.017

  13. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309-18. https://doi.org/10.1093/ cid/cit816

  14. Cesaro S, Giacchino M, Fioredda F, Barone A, Battisti L, Bezzio S, et al. Guidelines on vaccinations in paediatric haematology and oncology patients. Biomed Res Int. 2014;2014:707691. https://doi. org/10.1155/2014/707691

  15. Lehrnbecher T, Schubert R, Behl M, Koenig M, Rose MA, Koehl U, et al. Impaired pneumococcal immunity in children after treatment for acute lymphoblastic leukaemia. Br J Haematol. 2009;147(5):700-5. https://doi. org/10.1111/j.1365-2141.2009.07903.x

  16. Patel SR, Bate J, Borrow R, Heath PT. Serotype-specific pneumococcal antibody concentrations in children treated for acute leukaemia. Arch Dis Child. 2012;97:46-8. https://doi.org/10.1136/adc.2009.176271




2020     |     www.medigraphic.com